Digest Network Come funziona
Network
/
Società
Me
Non verificato

Merck Sharp & Dohme

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaMedicina - VarieSalute

8 comunicati stampa

Guarda tutti i comunicati
01/12/2025
Salute
Igiene alimentare
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Eventi
Finanza
Industria
Merck Showcases Data for Alzheimer's Disease Candidates MK-2214 and MK-1167 at CTAD 2025
Fonte
Merck Sharp & Dohme
Emittente
Business Wire
1.00
0
26/11/2025
Web e Social Network
Eventi
Finanza
Salute
Sanità
Scienza
Farmaceutica
Biotecnologia
Merck to Participate in the 8th Annual Evercore ISI HealthCONx Conference
Fonte
Merck Sharp & Dohme
Emittente
Business Wire
1.00
0
03/11/2025
Responsabilità sociale d'impresa
Volontariato/Solidarietà/Non profit
Associazioni/Professionisti
Cardiologia
Biotecnologia
Farmaceutica
Salute
Merck Foundation Launches $22 Million Initiative to Improve Cardiovascular Care in the U.S.
Fonte
Merck Sharp & Dohme
Emittente
Business Wire
1.00
0
09/10/2025
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Industria
Eventi
Merck Advances Oncology Innovation, Highlighting Progress in New Tumor Types and Earlier Stages of Disease at ESMO 2025
Fonte
Merck Sharp & Dohme
Emittente
Business Wire
1.00
0
06/10/2025
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Industria
Merck Expands Tulisokibart Clinical Development Program With Initiation of Phase 2b Trials in Three Additional Immune-Mediated Inflammatory Diseases
Fonte
Merck Sharp & Dohme
Emittente
Business Wire
1.00
0
30/09/2025
Scienza
Cardiologia
Biotecnologia
Farmaceutica
Salute
Igiene alimentare
Medicina - Varie
Industria
WINREVAIR™ (sotatercept-csrk) Reduced the Risk of Clinical Worsening Events by 76% Compared to Placebo in Patients Recently Diagnosed With PAH on Background Therapy in Phase 3 HYPERION Trial
Fonte
Merck Sharp & Dohme
Emittente
Business Wire
1.00
0
10/07/2025
Scienza
HIV, AIDS e malattie autoimmuni
Igiene alimentare
Medicina - Varie
Biotecnologia
Salute
Farmaceutica
Sanità
Industria
U.S. FDA Accepts New Drug Application for Merck’s Doravirine/Islatravir, an Investigational, Once-Daily, Oral, Two-Drug Regimen for Treatment of Adults with Virologically Suppressed HIV-1 Infection
Fonte
Merck Sharp & Dohme
Emittente
Business Wire
1.00
0
31/03/2025
Industria
Scienza
Biotecnologia
Farmaceutica
Salute
Igiene alimentare
Sanità
Medicina - Varie
WINREVAIR™ (sotatercept-csrk) Reduced the Risk of a Composite of All-Cause Death, Lung Transplantation and Hospitalization for Pulmonary Arterial Hypertension (PAH) by 76% Compared to Placebo in the Phase 3 ZENITH Trial
Fonte
Merck Sharp & Dohme
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0